An ‘impending crisis' has caused a team of doctors at St. Clare's Mercy Hospital to give their resignation notice
Five internal medicine specialists say they will quit their jobs come Oct. 1 because the work is no longer safe for them or the patients. The CBC's Ryan Cooke reports on what that could mean for other doctors, patients and how N.L. Health Services is responding.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Plans unveiled for NHS funding to be linked to patient feedback
NHS funding could be linked to patient feedback under new plans, with poorly performing services that "don't listen" penalised with less money. As part of the "10 Year Health Plan" to be unveiled next week, a new scheme will be trialled that will see patients asked to rate the service they received - and if they feel it should get a funding boost or not. It will be introduced first for services that have a track record of very poor performance and where there is evidence of patients "not being listened to", the government said. This will create a "powerful incentive for services to listen to feedback and improve patients' experience", it added. Sky News understands that it will not mean bonuses or pay increases for the best performing staff. NHS payment mechanisms will also be reformed to reward services that keep patients out of hospital as part of a new 'Year of Care Payments' initiative and the government's wider plan for change. Speaking to The Times, chief executive of the NHS Confederation Matthew Taylor expressed concerns about the trial. He told the newspaper: "Patient experience is determined by far more than their individual interaction with the clinician and so, unless this is very carefully designed and evaluated, there is a risk that providers could be penalised for more systemic issues, such as constraints around staffing or estates, that are beyond their immediate control to fix." He said that NHS leaders would be keen to "understand more about the proposal", because elements were "concerning". Read more from Sky News Health Secretary Wes Streeting said: "We will reward great patient care, so patient experience and clinical excellence are met with extra cash. These reforms are key to keeping people healthy and out of hospital, and to making the NHS sustainable for the long-term as part of the Plan for Change." In the raft of announcements in the 10 Year Health Plan, the government has said 201 bodies responsible for overseeing and running parts of the NHS in England will be scrapped. These include Healthwatch England, set up in 2012 to speak out on behalf of NHS and social care patients, the National Guardian's Office, created in 2015 to support NHS whistleblowers, and the Health Services Safety Investigations Body (HSSIB). Elsewhere, the new head of NHS England Sir Jim Mackey said key parts of the NHS appear "built to keep the public away because it's an inconvenience". "We've made it really hard, and we've probably all been on the end of it," he told the Daily Telegraph. "The ward clerk only works nine to five, or they're busy doing other stuff; the GP practice scrambles every morning."
Fox News
39 minutes ago
- Fox News
Body fat predicts major health risk that BMI misses, researchers say
Body mass index (BMI) may not be the most accurate predictor of death risk. A new study from the University of Florida found that BMI — a measurement that is commonly used to determine whether a person's weight is in a healthy range for their height — is "deeply flawed" in terms of predicting mortality. Instead, one's level of body fat is "far more accurate," concluded the study, which was published this week in the Annals of Family Medicine. To measure participants' body fat, the researchers used a method called bioelectrical impedance analysis (BIA), which uses a device to measure the resistance of body tissue to a small electrical current. Over a 15-year period, those who had high body fat were found to be 78% more likely to die than those who had healthy body fat levels, researchers found. They were also more than three times as likely to die of heart disease, the study noted. BMI — which is calculated by dividing weight by height, squared — was described as "entirely unreliable" in predicting the risk of death over a 15-year period from any cause. The study included 4,252 people in the U.S. and pulled data from the National Health and Nutrition Examination Survey. BMI should not be relied upon as a "vital sign" of health, according to senior author Frank Orlando, M.D., medical director of UF Health Family Medicine in Springhill. "I'm a family physician, and on a regular basis, we're faced with patients who have diabetes, heart disease, obesity and other conditions that are related to obesity," Orlando said in a press release for the study. "One of the routine measures we take alongside traditional vital signs is BMI. We use BMI to screen for a person having an issue with their body composition, but it's not as accurate for everyone as vital signs are," he added. BMI has been the international standard for measuring obesity since the 1980s, according to many sources, though some experts have questioned its validity. "I think the study shows it's time to go to an alternative that is now proven to be far better at the job." An individual is considered obese if their BMI is 30 or above, overweight if it is between 25 and 29.9, of "normal" weight in the range of 18.5 to 24.9, or underweight if lower than 18.5. While BMI is easy to calculate, one of its main limitations is that it cannot distinguish between muscle and fat mass, the researchers noted. "For example, people who are bodybuilders can really elevate their body mass index," Orlando said. "But they're healthy even with a BMI indicating that they're obese." "BMI is just so ingrained in how we think about body fat," Mainous added. "I think the study shows it's time to go to an alternative that is now proven to be far better at the job." Other methods, such as a DEXA (dual-energy X-ray absorptiometry) scan, may be even more accurate than BIA, but are much more expensive and not as accessible, the researchers noted. "If you talk to obesity researchers, they're going to say you have to use the DEXA scan because it's the most accurate," Mainous said in the release. "And that's probably true. But it's never going to be viable in a doctor's office or family practice." Dr. Stephen Vogel — a family medicine physician with PlushCare, a virtual health platform with primary care, therapy and weight management options — echoed the limitations of BMI. "It has been an easy measurement tool that helps us understand at-risk groups across various populations and demographics, but it doesn't provide accurate data from patient to patient," the North Carolina-based doctor, who was not involved in the study, told Fox News Digital. "These findings don't challenge the assumptions about BMI — they strengthen the message that new standards, delivered in a consistent and low-cost way, would provide better nuance for the individual when it comes to their overall physical health." "The main strengths of this study are a better correlation to an individual's risk of morbidity and mortality — however, the limitations lie in the fact that we don't have enough data to determine the right cutoff for these numbers, or to identify the right tools that will be both accurate and precise across the population," Vogel said. The researchers also acknowledged that body fat percentage thresholds haven't yet been as standardized as BMI and waist circumference. Also, the age range of the participants in the study was limited by the data source. "Future studies should extend this comparison of body fat to BMI in older adults," the researchers wrote. The study was also limited by focusing only on mortality as an outcome, they noted, without taking into account any developing diseases — such as heart failure or cancer — that could deepen the understanding of body fat as a risk factor. The goal, according to Vogel, is to have a cost-effective, consistent method that can be used across the population with reliable accuracy. "These data will drive better discussions in the doctor's office, as well as public health initiatives with the goal of improving the health of all." "Benefits would come in the form of a more detailed list of information that helps providers and patients make informed decisions about the patient's health, which is ideal," Vogel noted. "I'm hopeful there's enough buzz around these measures that steps will continue to be taken toward regular implementation." For more Health articles, visit The researchers are hopeful that once standards are validated, measuring body fat percentage with bioelectrical impedance analysis could become standard of care. They added, "These data will drive better discussions in the doctor's office, as well as public health initiatives with the goal of improving the health of all."
Yahoo
43 minutes ago
- Yahoo
Citi Expresses Optimism for Eli Lilly and Company (LLY)
Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Long Term Growth Stocks to Invest in Right Now. On June 25, Citi reported that 'compelling' data shows that Eli Lilly and Company (NYSE:LLY) and Novo Nordisk (NVO) have turned obesity into a treatable disease from a lifestyle-based condition. The firm models more than $40 billion in obesity sales by 2030, well above the consensus estimates of $25 billion. Citi stated that as the obesity space evolves from injectables to convenient orals, such as orforglipron, the emergence of a 'dynamic' consumer-centric market is possible, and LillyDirect by Eli Lilly and Company (NYSE:LLY) is well-positioned to connect high consumer visibility for orforglipron with global access. In a research note, Citi further stated that it estimated penetration rates via income-based tiers for pricing and out-of-pocket costs in low- and mid-body mass index patients. The results place Eli Lilly and Company's (NYSE:LLY) consumer platform opportunity at $15B, which is not assumed in the firm's model. It thus believes that Eli Lilly and Company's (NYSE:LLY) is in a position to expedite access outside the US, employing a centralized out-of-pocket payment model instead of the traditional country-by-country launch. It contended that an 'income-based tiered pricing of orforglipron via LillyDirect could unlock unprecedented volume, all the while allowing it to maintain overall pricing power.' Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies. Investors are bullish on Eli Lilly and Company (NYSE:LLY) due to its in-demand GLP-1 drugs, used to treat diabetes and obesity, which are still in their early growth stages, and the company's strong financials. While we acknowledge the potential of LKQ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
